Global Flu Treatment Market Overview
According to SPER Market Research, the Global Flu Treatment Market is estimated to reach USD 1.74 billion by 2032 with a CAGR of 5.25%.
Flu, commonly known as influenza, is a typical viral infection. Chills, aches in the muscles, fever, headaches, runny nose, cough, and others are common flu symptoms. The respiratory tract is primarily impacted by flu. Influenza viruses come in four main categories: influenza A, influenza B, influenza C, and influenza D. The influenza virus types A and B that cause seasonal flu most frequently each year are A and B. The market for influenza treatments has grown due to a number of causes, including an increase in healthcare spending and R&D spending on antiviral drugs. The expansion of government programmes to fight the flu and create reliable tests will support it. The rising cost of creating tests and equipment may restrain industry expansion. The limitations on accessibility and the availability of raw materials raise the cost of the final product.
Impact of COVID-19 on the Global Flu Treatment Market
The global market for flu medications is expanding as a result of ongoing advancements in technology and partnerships between private businesses and governmental agencies for the treatment of such pandemic flu. This is due to the Covid-19 disease, which is spreading continuously throughout the world and causing a significant number of deaths worldwide. Due to the global pandemic Covid-19, which has had a severe impact on a significant section of the population, the hospital pharmacies segment is predicted to exhibit the highest CAGR during the projection period. As a result, it is likely to encourage the market for flu medications to expand.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2032 |
| Base year considered | 2021 |
| Forecast period | 2022-2032 |
| Segments covered | By Type, By Medication, By Route of Administration, By Distribution Channel, By End User.
|
| Regions covered | Asia-Pacific, Europe, Middle East and Africa, North America, Latin America
|
| Companies Covered | AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., GSK plc, Lilly, Merck & Co. Inc., Mylan N.V., NATCO Pharma Limited, Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd.
|
Global Flu Treatment Market Segmentation:
1. By Type:
2. By Medication:
- Antiviral drugs
- Antihistamines
- Analgesics
- Others
3. By Route of Administration:
4. By Distribution Channel:
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
5. By End User:- Hospitals
- Homecare
- Specialty Clinics
- Others
6. By Region:
- Asia-Pacific
- Europe
- Middle East
- Africa
- North America
- Latin America
Key Topics Covered in the Report:
- Size of Global Flu Treatment Market (FY’2019-FY’2032)
- Overview of Global Flu Treatment Market
- Segmentation of Global Flu Treatment Market By Type (Type A, Type B, Type C)
- Segmentation of Global Flu Treatment Market By Medication (Antiviral drugs, Antihistamines, Analgesics, Others)
- Segmentation of Global Flu Treatment Market By Route of Administration (Oral, Parenteral, Others)
- Segmentation of Global Flu Treatment Market By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
- Segmentation of Global Flu Treatment Market By End User (Hospitals, Homecare, Specialty Clinics, Others)
- Statistical Snap of Global Flu Treatment Market
- Growth Analysis of Global Flu Treatment Market
- Problems and Challenges in Global Flu Treatment Market
- Competitive Landscape in the Global Flu Treatment Market
- Impact of COVID-19 and Demonetization on Global Flu Treatment Market
- Details on Recent Investment in Global Flu Treatment Market
- Competitive Analysis of Global Flu Treatment Market
- Major Players in the Global Flu Treatment Market
- SWOT Analysis of Global Flu Treatment Market
- Global Flu Treatment Market Future Outlook and Projections (FY’2019-FY’2032)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Flu Treatment Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Competitive Landscape
6.1 Global Flu Treatment Manufacturing Base Distribution, Sales Area, Product Type
6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Flu Treatment Market
7. Global Flu Treatment Market, By Type, 2019-2032 (USD Million)
7.1. Type A
7.2. Type B
7.3. Type C
8. Global Flu Treatment Market, By Medication, 2019-2032 (USD Million)
8.1. Antiviral drugs
8.2. Antihistamines
8.3. Analgesics
8.4. Others
9. Global Flu Treatment Market, By Route of Administration, 2019-2032 (USD Million)
9.1. Oral
9.2. Parenteral
9.3. Others
10. Global Flu Treatment Market, By Distribution Channel, 2019-2032 (USD Million)
10.1. Hospital Pharmacy
10.2. Online Pharmacy
10.3. Retail Pharmacy
11. Global Flu Treatment Market, By End User, 2019-2032 (USD Million)
11.1. Hospitals
11.2. Homecare
11.3. Specialty Clinics
11.4. Others
12. Global Flu Treatment Market, By Region, 2019-2032 (USD Million)
12.1. Global Flu Treatment Market Size and Market Share by Region (2019-2025)
12.2. Global Flu Treatment Market Size and Market Share by Region (2026-2032)
12.3. Asia-Pacific
12.3.1. Australia
12.3.2. China
12.3.3. India
12.3.4. Japan
12.3.5. South Korea
12.3.6. Rest of Asia-Pacific
12.4. Europe
12.4.1. France
12.4.2. Germany
12.4.3. Italy
12.4.4. Spain
12.4.5. United Kingdom
12.4.6. Rest of Europe
12.5. Middle East and Africa
12.5.1. Kingdom of Saudi Arabia
12.5.2. United Arab Emirates
12.5.3. Rest of Middle East & Africa
12.6. North America
12.6.1. Canada
12.6.2. Mexico
12.6.3. United States
12.7. Latin America
12.7.1. Argentina
12.7.2. Brazil
12.7.3. Rest of Latin America
13. Company Profiles
13.1. AstraZeneca
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Product summary
13.1.4. Recent developments
13.2. Bayer AG
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments
13.3. Bristol-Myers Squibb Company
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Product summary
13.3.4. Recent developments
13.4. F. Hoffmann-La Roche Ltd.
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments
13.5. GSK plc
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Product summary
13.5.4. Recent developments
13.6. Lilly
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Product summary
13.6.4. Recent developments
13.7. Merck & Co. Inc.
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Product summary
13.7.4. Recent developments
13.8. Mylan N.V.
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Product summary
13.8.4. Recent developments
13.9. NATCO Pharma Limited
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Product summary
13.9.4. Recent developments
13.10. Novartis AG
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Product summary
13.10.4. Recent developments
13.11. Pfizer Inc.
13.11.1. Company details
13.11.2. Financial outlook
13.11.3. Product summary
13.11.4. Recent developments
13.12. Sanofi
13.12.1. Company details
13.12.2. Financial outlook
13.12.3. Product summary
13.12.4. Recent developments
13.13. Sun Pharmaceutical Industries Ltd.
13.13.1. Company details
13.13.2. Financial outlook
13.13.3. Product summary
13.13.4. Recent developments
14. List of Abbreviations
15. Reference Links
16. Conclusion
17. Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
